Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.94 INR -6.34% Market Closed
Market Cap: 525.8m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

Transgene Biotek Ltd
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Transgene Biotek Ltd
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Transgene Biotek Ltd
BSE:526139
Other Liabilities
â‚ą1.2B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Other Liabilities
â‚ą68.7m
CAGR 3-Years
7%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Other Liabilities
â‚ą21.4m
CAGR 3-Years
3%
CAGR 5-Years
40%
CAGR 10-Years
25%
Hester Biosciences Ltd
NSE:HESTERBIO
Other Liabilities
â‚ą607.6m
CAGR 3-Years
43%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Biocon Ltd
NSE:BIOCON
Other Liabilities
â‚ą16.2B
CAGR 3-Years
-16%
CAGR 5-Years
11%
CAGR 10-Years
11%
Panacea Biotec Ltd
NSE:PANACEABIO
Other Liabilities
â‚ą451.8m
CAGR 3-Years
-46%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
No Stocks Found

Transgene Biotek Ltd
Glance View

Market Cap
525.8m INR
Industry
Biotechnology

Transgene Biotek Ltd. is a biotechnology company, which manufactures and sells diagnostic kits. The company is headquartered in Medak, Telangana. The firm is engaged in a single business segment of Bulk Drugs. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The firm offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. The company also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-0404, is used for the treatment of metastatic liver cancer. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

TRABI Intrinsic Value
0.29 INR
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Transgene Biotek Ltd's Other Liabilities?
Other Liabilities
1.2B INR

Based on the financial report for Sep 30, 2024, Transgene Biotek Ltd's Other Liabilities amounts to 1.2B INR.

What is Transgene Biotek Ltd's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
0%

Over the last year, the Other Liabilities growth was 0%.

Back to Top